...in mouse models of neurodegenerative disease, stroke and viral encephalitis. Discovery stage CNR2 agonists from Organix Inc....

...Galenea received exclusive, worldwide rights from Organix and the universities to develop and commercialize preclinical serotonin...
...to develop and commercialize preclinical serotonin (5-HT2C) receptor agonists to treat obesity and related disorders. Organix...
...undisclosed upfront payment and be eligible for milestones and royalties. Galenea Corp. , Cambridge, Mass. Organix Inc....

...Mass.) received exclusive, worldwide rights to develop and commercialize selective serotonin (5-HT2C) receptor agonists from Organix...
...at Chapel Hill. Galenea will develop the preclinical compounds to treat obesity and related disorders. Organix...